Goldman Sachs’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.4M | Sell |
379,596
-75,316
| -17% | -$4.39M | ﹤0.01% | 2371 |
|
|
2025
Q4 | $27M | Sell |
454,912
-1,836,048
| -80% | -$100M | ﹤0.01% | 2087 |
|
|
2025
Q3 | $124M | Buy |
2,290,960
+185,355
| +9% | +$10.6M | 0.02% | 809 |
|
|
2025
Q2 | $116M | Buy |
2,105,605
+512,642
| +32% | +$30.2M | 0.02% | 809 |
|
|
2025
Q1 | $113M | Buy |
1,592,963
+1,083,512
| +213% | +$72.9M | 0.02% | 729 |
|
|
2024
Q4 | $33.5M | Buy |
509,451
+59,485
| +13% | +$3.98M | 0.01% | 1631 |
|
|
2024
Q3 | $31.6M | Sell |
449,966
-109,836
| -20% | -$9.18M | 0.01% | 1642 |
|
|
2024
Q2 | $46.1M | Sell |
559,802
-133,422
| -19% | -$11.1M | 0.01% | 1217 |
|
|
2024
Q1 | $60.5M | Sell |
693,224
-214,557
| -24% | -$19.2M | 0.01% | 1047 |
|
|
2023
Q4 | $87.5M | Sell |
907,781
-71,814
| -7% | -$6.35M | 0.02% | 853 |
|
|
2023
Q3 | $86.7M | Sell |
979,595
-455,302
| -32% | -$40.5M | 0.02% | 793 |
|
|
2023
Q2 | $124M | Buy |
1,434,897
+306,018
| +27% | +$28.8M | 0.03% | 621 |
|
|
2023
Q1 | $110M | Sell |
1,128,879
-42,172
| -4% | -$4.37M | 0.03% | 658 |
|
|
2022
Q4 | $121M | Buy |
1,171,051
+388,026
| +50% | +$36.4M | 0.03% | 627 |
|
|
2022
Q3 | $66.4M | Sell |
783,025
-39,673
| -5% | -$3.53M | 0.02% | 919 |
|
|
2022
Q2 | $68.2M | Buy |
822,698
+114,080
| +16% | +$9.08M | 0.02% | 909 |
|
|
2022
Q1 | $54.6M | Sell |
708,618
-106,449
| -13% | -$8.91M | 0.01% | 1193 |
|
|
2021
Q4 | $72M | Sell |
815,067
-671,512
| -45% | -$55.4M | 0.01% | 1039 |
|
|
2021
Q3 | $115M | Buy |
1,486,579
+235,441
| +19% | +$18.6M | 0.02% | 672 |
|
|
2021
Q2 | $104M | Buy |
1,251,138
+38,296
| +3% | +$3.04M | 0.02% | 708 |
|
|
2021
Q1 | $91.6M | Sell |
1,212,842
-393,128
| -24% | -$32.1M | 0.02% | 708 |
|
|
2020
Q4 | $141M | Sell |
1,605,970
-76,103
| -5% | -$6.03M | 0.04% | 453 |
|
|
2020
Q3 | $128M | Sell |
1,682,073
-226,417
| -12% | -$22.9M | 0.04% | 473 |
|
|
2020
Q2 | $235M | Buy |
1,908,490
+225,983
| +13% | +$22.5M | 0.07% | 255 |
|
|
2020
Q1 | $142M | Buy |
1,682,507
+69,790
| +4% | +$6.01M | 0.05% | 368 |
|
|
2019
Q4 | $136M | Buy |
1,612,717
+143,113
| +10% | +$10.8M | 0.03% | 547 |
|
|
2019
Q3 | $99.1M | Sell |
1,469,604
-498,011
| -25% | -$38.4M | 0.03% | 663 |
|
|
2019
Q2 | $169M | Sell |
1,967,615
-207,951
| -10% | -$17.8M | 0.05% | 434 |
|
|
2019
Q1 | $193M | Buy |
2,175,566
+146,363
| +7% | +$13.6M | 0.06% | 371 |
|
|
2018
Q4 | $173M | Sell |
2,029,203
-305,226
| -13% | -$29M | 0.06% | 366 |
|
|
2018
Q3 | $226M | Sell |
2,334,429
-407,815
| -15% | -$40.7M | 0.06% | 364 |
|
|
2018
Q2 | $258M | Sell |
2,742,244
-484,416
| -15% | -$42.4M | 0.07% | 293 |
|
|
2018
Q1 | $262M | Buy |
3,226,660
+361,158
| +13% | +$31M | 0.07% | 317 |
|
|
2017
Q4 | $256M | Buy |
2,865,502
+506,352
| +21% | +$44M | 0.06% | 359 |
|
|
2017
Q3 | $220M | Buy |
2,359,150
+395,081
| +20% | +$34.9M | 0.05% | 381 |
|
|
2017
Q2 | $178M | Buy |
1,964,069
+424,610
| +28% | +$38.6M | 0.05% | 463 |
|
|
2017
Q1 | $135M | Buy |
1,539,459
+158,527
| +11% | +$14.1M | 0.04% | 564 |
|
|
2016
Q4 | $114M | Buy |
1,380,932
+49,132
| +4% | +$4.23M | 0.03% | 690 |
|
|
2016
Q3 | $123M | Buy |
1,331,800
+641,098
| +93% | +$60.4M | 0.04% | 598 |
|
|
2016
Q2 | $53.7M | Sell |
690,702
-153,605
| -18% | -$13.1M | 0.02% | 1065 |
|
|
2016
Q1 | $69.6M | Sell |
844,307
-221,233
| -21% | -$18M | 0.02% | 858 |
|
|
2015
Q4 | $112M | Buy |
1,065,540
+671,252
| +170% | +$70.1M | 0.04% | 610 |
|
|
2015
Q3 | $41.5M | Buy |
394,288
+140,873
| +56% | +$18.8M | 0.01% | 1181 |
|
|
2015
Q2 | $34.7M | Sell |
253,415
-674,687
| -73% | -$83.6M | 0.01% | 1389 |
|
|
2015
Q1 | $116M | Buy |
928,102
+513,073
| +124% | +$54.4M | 0.04% | 571 |
|
|
2014
Q4 | $37.5M | Sell |
415,029
-37,405
| -8% | -$3.11M | 0.01% | 1339 |
|
|
2014
Q3 | $32.6M | Sell |
452,434
-505,079
| -53% | -$33.2M | 0.01% | 1414 |
|
|
2014
Q2 | $59.6M | Buy |
957,513
+360,399
| +60% | +$21.8M | 0.02% | 975 |
|
|
2014
Q1 | $40.7M | Sell |
597,114
-129,842
| -18% | -$9.57M | 0.01% | 1209 |
|
|
2013
Q4 | $51.1M | Sell |
726,956
-581,701
| -44% | -$39.5M | 0.02% | 1024 |
|
|
2013
Q3 | $94.4M | Sell |
1,308,657
-101,098
| -7% | -$6.72M | 0.03% | 624 |
|
|
2013
Q2 | $78.6M | Buy |
+1,409,755
| New | +$87.9M | 0.03% | 650 |
|
Other funds holding BMRN
VCM
VPM
Goldman Sachs's BMRN Position: Q1 2026 in Review
Goldman Sachs reduced its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q1 2026, selling an estimated $4.39M and leaving 379,596 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2371.
Goldman Sachs first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $262M in Q1 2018. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Goldman Sachs held 379,596 shares of BioMarin Pharmaceuticals worth $21.4M as of Q1 2026.
- Goldman Sachs sold 75,316 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.39M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2371 holding.
- Goldman Sachs first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's BioMarin Pharmaceuticals position peaked at $262M in Q1 2018.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.